Authors


John Shanahan, BA

Latest:

The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral Center

COVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.


Divya Asti, MD

Latest:

Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials

The aim of this meta-analysis is to analyze the efficacy of these drugs in the treatment of mCRPC in terms of progression-free survival (PFS) and overall survival (OS), using the results of completed trials.


Jessica Hergert

Latest:

Survival Boost Noted With Addition of Durvalumab to Chemotherapy for BTC

When compared with placebo and chemotherapy, durvalumab plus gemcitabine and cisplatin was superior in terms of overall survival in the treatment of advanced biliary tract cancer.




Evelyn Lilian Beas-Lozano, MD

Latest:

Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors

A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.






Matthew T. Campbell, MD, MS

Latest:

Scratching the Surface in Managing Advanced RCC

Matthew T. Campbell, MD, MS, discusses CAR T-cell therapy and immunotherapy advances in renal cell carcinoma.


Murali Janakiram, MD, MS

Latest:

CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple Myeloma

Panelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.




Karen H. Lu, MD

Latest:

Karen H. Lu, MD, on Next Steps in Evaluating Genetic Testing in Underrepresented Minorities

The MD Anderson Cancer Center expert discussed further research in delivering online accessible genetic testing.


Eileen O’Reilly, MD

Latest:

Treatment Paradigm for Early-Stage Pancreatic Cancer Diagnosis

With Eileen O’Reilly, MD, the Oncology Brothers discuss the current treatment paradigm for early-stage pancreatic cancer, focusing on diagnostic strategies, surgical options, and adjuvant therapies to improve patient outcomes.


Mariana Licano-Zubiate, MD

Latest:

Metastatic Renal Cell Carcinoma With Sarcomatoid Features

In this installement of Clinical Quandaries, Abigail Mateos-Soria, MD, and colleagues present a case of an 38-year-old woman who has a 3-month history of fatigue, dyspnea, significant weight loss, and severe left flank pain.



Jeffrey M. Ryckman, MD

Latest:

Adverse Effects Associated with SBRT in Patients With HCC

The panel discusses adverse effects associated with stereotactic body radiation therapy, and the Oncology Brothers provide a recap of the entire discussion.



Anjali Hari, MD

Latest:

Anjali Hari, MD, Highlights the Rationale for Assessing HIPEC in Frail and Non-Frail Ovarian Cancer

Anjali Y. Hari, MD, speaks to the rationale for examining hyperthermic intraperitoneal chemotherapy in a population of frail and non-frail patients with ovarian cancer.


Sunraj Tharu, BSc

Latest:

Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic Review

Danazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.


Linie Chi, NP

Latest:

Renal Cell Carcinoma: Practical Advice for Patients, Caregivers, and Physicians

Practical advice on the management of renal cell carcinoma provided for healthcare professionals, patients, and caregivers alike.



Samia Asif, MBBS

Latest:

Unusual Clinical Presentation of Clear Cell Sarcoma in a Young Woman

A young woman presents with painless lumps to the emergency department and is later diagnosed with clear cell carcinoma.


Alison Conlin, MD

Latest:

Metastatic Triple-Negative Breast Cancer: Unmet Needs and Future Directions in Care

Expert oncologists highlight remaining unmet needs in the setting of metastatic triple-negative breast cancer and look toward future evolutions in care.


Chengping Hu, MD

Latest:

Profilin 1 Protein and Its Implications for Cancers

Profilin 1, or PFN1, is a key actin-binding protein that is involved in various cellular activities, such as cell motility, survival, and membrane trafficking. By summarizing the functions of PFN1 in cancer, investigators hope to better understand the mechanisms of PFN1 in cancer progression.


Irina Melnichenko, MD

Latest:

How to Treat Metastatic Malignant Triton Tumor in an Adolescent

A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.



Douglas Braun, CSP, PharmD, RPh

Latest:

Expert Commentary on the Product Profile of Umbralisib for Lymphoma

In an interview with ONCOLOGY®, Douglas Braun, CSP, PharmD, RPh, offers a comprehensive review of real-world treatment considerations of umbralisib as therapy for patients with previously treated follicular and marginal zone lymphoma.